3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Glioblastoma
45
Neuroblastoma
16
Glioma
16
Brain Neoplasms
14
Astrocytoma
10
Neoplasms
8
Rhabdomyosarcoma
7
Sarcoma, Ewing
6
Recurrence
5
Oligodendroglioma
5
Medulloblastoma
5
Sarcoma
4
Osteosarcoma
4
Melanoma
4
Small Cell Lung Carcinoma
3
Neuroendocrine Tumors
3
Neuroectodermal Tumors, Primitive
3
Lymphoma
3
Gliosarcoma
3
Diffuse Intrinsic Pontine Glioma
3
Wilms Tumor
2
Rhabdoid Tumor
2
Pyloric Stenosis, Hypertrophic
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Ganglioneuroblastoma
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Interventions
lutetium Lu 177 dotatate
3
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
zimberelimab
1
pasireotide
1
cabozantinib
1
amino-acid, glucose, and electrolyte solution
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Somatostatin
1
Radiosurgery
1
Everolimus
1
Disulfides
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
Clear all
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled